ARS Pharmaceuticals Highlights neffy’s Cost and Usability Advantages at AAAAI 2026

Event summary

  • ARS Pharmaceuticals will present five posters and two late-breaking partner presentations at the 2026 AAAAI Annual Meeting, showcasing neffy’s clinical and economic advantages.
  • Data indicates neffy’s longer shelf life and needle-free design could make it more cost-effective and preferred by patients over traditional auto-injectors.
  • Patient preference studies suggest a 25%+ increase in value perception for nasal epinephrine due to needle aversion.
  • Presentations include pharmacokinetic comparisons, treatment adherence, and societal value analyses of neffy.

The big picture

ARS Pharmaceuticals is positioning neffy as a disruptive alternative to traditional epinephrine auto-injectors, emphasizing its needle-free design, longer shelf life, and potential cost savings. The company’s focus on patient preference and real-world usability aligns with broader industry trends toward more accessible and user-friendly emergency treatments. If successful, neffy could capture significant market share in the $2 billion global anaphylaxis treatment market.

What we're watching

Market Adoption
Whether neffy can overcome patient and caregiver inertia to switch from established auto-injectors.
Regulatory Dynamics
The pace at which neffy gains broader regulatory approvals beyond the U.S. and EU.
Competitive Positioning
How ARS Pharmaceuticals leverages clinical data to differentiate neffy in a crowded epinephrine market.